img

Global Antihemophilic Factor Drug Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antihemophilic Factor Drug Market Research Report 2024

Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
According to Mr Accuracy reports new survey, global Antihemophilic Factor Drug market is projected to reach US$ 796 million in 2029, increasing from US$ 541 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antihemophilic Factor Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antihemophilic Factor Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Bayer
Takeda
Novo Nordisk
Pfizer
Grifols
CSL Behring
Sanofi
Cigna
Octapharma
GC Pharma
Hualan Biological Engineering
Shanghai RAAS blood products
Segment by Type
250 IU
500 IU
1000 IU
1500 IU
2000 IU
3000 IU
4000 IU
Other potencies

Segment by Application


Adult
Pediatric

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Antihemophilic Factor Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Antihemophilic Factor Drug Market Overview
1.1 Product Overview and Scope of Antihemophilic Factor Drug
1.2 Antihemophilic Factor Drug Segment by Type
1.2.1 Global Antihemophilic Factor Drug Market Value Comparison by Type (2024-2034)
1.2.2 250 IU
1.2.3 500 IU
1.2.4 1000 IU
1.2.5 1500 IU
1.2.6 2000 IU
1.2.7 3000 IU
1.2.8 4000 IU
1.2.9 Other potencies
1.3 Antihemophilic Factor Drug Segment by Application
1.3.1 Global Antihemophilic Factor Drug Market Value by Application: (2024-2034)
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts
1.4.1 Global Antihemophilic Factor Drug Revenue 2018-2029
1.4.2 Global Antihemophilic Factor Drug Sales 2018-2029
1.4.3 Global Antihemophilic Factor Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Antihemophilic Factor Drug Market Competition by Manufacturers
2.1 Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Antihemophilic Factor Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Antihemophilic Factor Drug Average Price by Manufacturers (2018-2024)
2.4 Global Antihemophilic Factor Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antihemophilic Factor Drug, Product Type & Application
2.7 Antihemophilic Factor Drug Market Competitive Situation and Trends
2.7.1 Antihemophilic Factor Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antihemophilic Factor Drug Players Market Share by Revenue
2.7.3 Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antihemophilic Factor Drug Retrospective Market Scenario by Region
3.1 Global Antihemophilic Factor Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antihemophilic Factor Drug Global Antihemophilic Factor Drug Sales by Region: 2018-2029
3.2.1 Global Antihemophilic Factor Drug Sales by Region: 2018-2024
3.2.2 Global Antihemophilic Factor Drug Sales by Region: 2024-2029
3.3 Global Antihemophilic Factor Drug Global Antihemophilic Factor Drug Revenue by Region: 2018-2029
3.3.1 Global Antihemophilic Factor Drug Revenue by Region: 2018-2024
3.3.2 Global Antihemophilic Factor Drug Revenue by Region: 2024-2029
3.4 North America Antihemophilic Factor Drug Market Facts & Figures by Country
3.4.1 North America Antihemophilic Factor Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antihemophilic Factor Drug Sales by Country (2018-2029)
3.4.3 North America Antihemophilic Factor Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antihemophilic Factor Drug Market Facts & Figures by Country
3.5.1 Europe Antihemophilic Factor Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antihemophilic Factor Drug Sales by Country (2018-2029)
3.5.3 Europe Antihemophilic Factor Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antihemophilic Factor Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Antihemophilic Factor Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antihemophilic Factor Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Antihemophilic Factor Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antihemophilic Factor Drug Market Facts & Figures by Country
3.7.1 Latin America Antihemophilic Factor Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antihemophilic Factor Drug Sales by Country (2018-2029)
3.7.3 Latin America Antihemophilic Factor Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antihemophilic Factor Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Antihemophilic Factor Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antihemophilic Factor Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antihemophilic Factor Drug Sales by Type (2018-2029)
4.1.1 Global Antihemophilic Factor Drug Sales by Type (2018-2024)
4.1.2 Global Antihemophilic Factor Drug Sales by Type (2024-2029)
4.1.3 Global Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
4.2 Global Antihemophilic Factor Drug Revenue by Type (2018-2029)
4.2.1 Global Antihemophilic Factor Drug Revenue by Type (2018-2024)
4.2.2 Global Antihemophilic Factor Drug Revenue by Type (2024-2029)
4.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
4.3 Global Antihemophilic Factor Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Antihemophilic Factor Drug Sales by Application (2018-2029)
5.1.1 Global Antihemophilic Factor Drug Sales by Application (2018-2024)
5.1.2 Global Antihemophilic Factor Drug Sales by Application (2024-2029)
5.1.3 Global Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
5.2 Global Antihemophilic Factor Drug Revenue by Application (2018-2029)
5.2.1 Global Antihemophilic Factor Drug Revenue by Application (2018-2024)
5.2.2 Global Antihemophilic Factor Drug Revenue by Application (2024-2029)
5.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
5.3 Global Antihemophilic Factor Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Bayer Antihemophilic Factor Drug Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Takeda
6.2.1 Takeda Corporation Information
6.2.2 Takeda Description and Business Overview
6.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Takeda Antihemophilic Factor Drug Product Portfolio
6.2.5 Takeda Recent Developments/Updates
6.3 Novo Nordisk
6.3.1 Novo Nordisk Corporation Information
6.3.2 Novo Nordisk Description and Business Overview
6.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio
6.3.5 Novo Nordisk Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Pfizer Antihemophilic Factor Drug Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Corporation Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Grifols Antihemophilic Factor Drug Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 CSL Behring
6.6.1 CSL Behring Corporation Information
6.6.2 CSL Behring Description and Business Overview
6.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 CSL Behring Antihemophilic Factor Drug Product Portfolio
6.6.5 CSL Behring Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Sanofi Antihemophilic Factor Drug Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Cigna
6.8.1 Cigna Corporation Information
6.8.2 Cigna Description and Business Overview
6.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Cigna Antihemophilic Factor Drug Product Portfolio
6.8.5 Cigna Recent Developments/Updates
6.9 Octapharma
6.9.1 Octapharma Corporation Information
6.9.2 Octapharma Description and Business Overview
6.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Octapharma Antihemophilic Factor Drug Product Portfolio
6.9.5 Octapharma Recent Developments/Updates
6.10 GC Pharma
6.10.1 GC Pharma Corporation Information
6.10.2 GC Pharma Description and Business Overview
6.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 GC Pharma Antihemophilic Factor Drug Product Portfolio
6.10.5 GC Pharma Recent Developments/Updates
6.11 Hualan Biological Engineering
6.11.1 Hualan Biological Engineering Corporation Information
6.11.2 Hualan Biological Engineering Antihemophilic Factor Drug Description and Business Overview
6.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio
6.11.5 Hualan Biological Engineering Recent Developments/Updates
6.12 Shanghai RAAS blood products
6.12.1 Shanghai RAAS blood products Corporation Information
6.12.2 Shanghai RAAS blood products Antihemophilic Factor Drug Description and Business Overview
6.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio
6.12.5 Shanghai RAAS blood products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antihemophilic Factor Drug Industry Chain Analysis
7.2 Antihemophilic Factor Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antihemophilic Factor Drug Production Mode & Process
7.4 Antihemophilic Factor Drug Sales and Marketing
7.4.1 Antihemophilic Factor Drug Sales Channels
7.4.2 Antihemophilic Factor Drug Distributors
7.5 Antihemophilic Factor Drug Customers
8 Antihemophilic Factor Drug Market Dynamics
8.1 Antihemophilic Factor Drug Industry Trends
8.2 Antihemophilic Factor Drug Market Drivers
8.3 Antihemophilic Factor Drug Market Challenges
8.4 Antihemophilic Factor Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Antihemophilic Factor Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Antihemophilic Factor Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Antihemophilic Factor Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Antihemophilic Factor Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Antihemophilic Factor Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Antihemophilic Factor Drug Average Price (USD/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antihemophilic Factor Drug, Product Type & Application
Table 12. Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antihemophilic Factor Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Antihemophilic Factor Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Antihemophilic Factor Drug Sales Market Share by Region (2018-2024)
Table 19. Global Antihemophilic Factor Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Antihemophilic Factor Drug Sales Market Share by Region (2024-2029)
Table 21. Global Antihemophilic Factor Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Antihemophilic Factor Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Antihemophilic Factor Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Antihemophilic Factor Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Antihemophilic Factor Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Antihemophilic Factor Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Antihemophilic Factor Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Antihemophilic Factor Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Antihemophilic Factor Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Antihemophilic Factor Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Antihemophilic Factor Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Antihemophilic Factor Drug Sales Market Share by Type (2018-2024)
Table 53. Global Antihemophilic Factor Drug Sales Market Share by Type (2024-2029)
Table 54. Global Antihemophilic Factor Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Antihemophilic Factor Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Antihemophilic Factor Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Antihemophilic Factor Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2018-2024)
Table 59. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2024-2029)
Table 60. Global Antihemophilic Factor Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Antihemophilic Factor Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Antihemophilic Factor Drug Sales Market Share by Application (2018-2024)
Table 63. Global Antihemophilic Factor Drug Sales Market Share by Application (2024-2029)
Table 64. Global Antihemophilic Factor Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Antihemophilic Factor Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Antihemophilic Factor Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Antihemophilic Factor Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2018-2024)
Table 69. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2024-2029)
Table 70. Bayer Corporation Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 73. Bayer Antihemophilic Factor Drug Product
Table 74. Bayer Recent Developments/Updates
Table 75. Takeda Corporation Information
Table 76. Takeda Description and Business Overview
Table 77. Takeda Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 78. Takeda Antihemophilic Factor Drug Product
Table 79. Takeda Recent Developments/Updates
Table 80. Novo Nordisk Corporation Information
Table 81. Novo Nordisk Description and Business Overview
Table 82. Novo Nordisk Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 83. Novo Nordisk Antihemophilic Factor Drug Product
Table 84. Novo Nordisk Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 88. Pfizer Antihemophilic Factor Drug Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Grifols Corporation Information
Table 91. Grifols Description and Business Overview
Table 92. Grifols Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 93. Grifols Antihemophilic Factor Drug Product
Table 94. Grifols Recent Developments/Updates
Table 95. CSL Behring Corporation Information
Table 96. CSL Behring Description and Business Overview
Table 97. CSL Behring Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 98. CSL Behring Antihemophilic Factor Drug Product
Table 99. CSL Behring Recent Developments/Updates
Table 100. Sanofi Corporation Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 103. Sanofi Antihemophilic Factor Drug Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Cigna Corporation Information
Table 106. Cigna Description and Business Overview
Table 107. Cigna Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 108. Cigna Antihemophilic Factor Drug Product
Table 109. Cigna Recent Developments/Updates
Table 110. Octapharma Corporation Information
Table 111. Octapharma Description and Business Overview
Table 112. Octapharma Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 113. Octapharma Antihemophilic Factor Drug Product
Table 114. Octapharma Recent Developments/Updates
Table 115. GC Pharma Corporation Information
Table 116. GC Pharma Description and Business Overview
Table 117. GC Pharma Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. GC Pharma Antihemophilic Factor Drug Product
Table 119. GC Pharma Recent Developments/Updates
Table 120. Hualan Biological Engineering Corporation Information
Table 121. Hualan Biological Engineering Description and Business Overview
Table 122. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 123. Hualan Biological Engineering Antihemophilic Factor Drug Product
Table 124. Hualan Biological Engineering Recent Developments/Updates
Table 125. Shanghai RAAS blood products Corporation Information
Table 126. Shanghai RAAS blood products Description and Business Overview
Table 127. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 128. Shanghai RAAS blood products Antihemophilic Factor Drug Product
Table 129. Shanghai RAAS blood products Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Antihemophilic Factor Drug Distributors List
Table 133. Antihemophilic Factor Drug Customers List
Table 134. Antihemophilic Factor Drug Market Trends
Table 135. Antihemophilic Factor Drug Market Drivers
Table 136. Antihemophilic Factor Drug Market Challenges
Table 137. Antihemophilic Factor Drug Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antihemophilic Factor Drug
Figure 2. Global Antihemophilic Factor Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Antihemophilic Factor Drug Market Share by Type in 2022 & 2029
Figure 4. 250 IU Product Picture
Figure 5. 500 IU Product Picture
Figure 6. 1000 IU Product Picture
Figure 7. 1500 IU Product Picture
Figure 8. 2000 IU Product Picture
Figure 9. 3000 IU Product Picture
Figure 10. 4000 IU Product Picture
Figure 11. Other potencies Product Picture
Figure 12. Global Antihemophilic Factor Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 13. Global Antihemophilic Factor Drug Market Share by Application in 2022 & 2029
Figure 14. Adult
Figure 15. Pediatric
Figure 16. Global Antihemophilic Factor Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Antihemophilic Factor Drug Market Size (2018-2029) & (US$ Million)
Figure 18. Global Antihemophilic Factor Drug Sales (2018-2029) & (K Units)
Figure 19. Global Antihemophilic Factor Drug Average Price (USD/Unit) & (2018-2029)
Figure 20. Antihemophilic Factor Drug Report Years Considered
Figure 21. Antihemophilic Factor Drug Sales Share by Manufacturers in 2022
Figure 22. Global Antihemophilic Factor Drug Revenue Share by Manufacturers in 2022
Figure 23. The Global 5 and 10 Largest Antihemophilic Factor Drug Players: Market Share by Revenue in 2022
Figure 24. Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 25. Global Antihemophilic Factor Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 26. North America Antihemophilic Factor Drug Sales Market Share by Country (2018-2029)
Figure 27. North America Antihemophilic Factor Drug Revenue Market Share by Country (2018-2029)
Figure 28. U.S. Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Canada Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Europe Antihemophilic Factor Drug Sales Market Share by Country (2018-2029)
Figure 31. Europe Antihemophilic Factor Drug Revenue Market Share by Country (2018-2029)
Figure 32. Germany Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. France Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. U.K. Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Italy Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Russia Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Asia Pacific Antihemophilic Factor Drug Sales Market Share by Region (2018-2029)
Figure 38. Asia Pacific Antihemophilic Factor Drug Revenue Market Share by Region (2018-2029)
Figure 39. China Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Japan Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. South Korea Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. India Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Australia Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Taiwan Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Indonesia Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Thailand Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Malaysia Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Philippines Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Antihemophilic Factor Drug Sales Market Share by Country (2018-2029)
Figure 50. Latin America Antihemophilic Factor Drug Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East & Africa Antihemophilic Factor Drug Sales Market Share by Country (2018-2029)
Figure 55. Middle East & Africa Antihemophilic Factor Drug Revenue Market Share by Country (2018-2029)
Figure 56. Turkey Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. UAE Antihemophilic Factor Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Global Sales Market Share of Antihemophilic Factor Drug by Type (2018-2029)
Figure 60. Global Revenue Market Share of Antihemophilic Factor Drug by Type (2018-2029)
Figure 61. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2018-2029)
Figure 62. Global Sales Market Share of Antihemophilic Factor Drug by Application (2018-2029)
Figure 63. Global Revenue Market Share of Antihemophilic Factor Drug by Application (2018-2029)
Figure 64. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2018-2029)
Figure 65. Antihemophilic Factor Drug Value Chain
Figure 66. Antihemophilic Factor Drug Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries